V1, NCI has updated its PDQ site and LGND's clinical trials look stronger than ever. For Panretin, the oral trial for Kaposi Sarcoma has been updated to include the names and addresses of the AIDS consortium involved in the study. Targretin trials have also been updated. There are 4 new trials listed. One for combination therapy with interferon for renal cancer and 3 phase II/III oral trials for treating CTCL. There are now 10 trails listed for Panretin and 10 trials listed for Targretin (I think the total number of trials for these two drugs is more than double the number listed at PDQ).
Here are the AIDS consortium participants:
Robert D. Mass, Principal Investigator, Ph: 415-202-2859
Kaiser Permanente Medical Group - San Francisco
San Francisco, California, USA
Lawrence D. Kaplan, Principal Investigator, Ph: 415-476-4082
San Francisco General Hospital Medical Center
San Francisco, California, USA
Ronald T. Mitsuyasu, Principal Investigator, Ph: 310-206-8359
UCLA Clinical AIDS Research and Education (CARE) Center
Los Angeles, California, USA
Bryan R. Leigh, Principal Investigator, Ph: 916-734-8252
University of California Davis Cancer Center
Sacramento, California, USA
M. Wayne Saville, Principal Investigator, Ph: 619-543-2214
University of California San Diego Cancer Center
San Diego, California, USA
Alexandra M. Levine, Principal Investigator, Ph: 213-764-3913
USC/Norris Comprehensive Cancer Center
Los Angeles, California, USA
Patricia A. Cornett, Principal Investigator, Ph: 415-221-4810
Veterans Administration Medical Center - San Francisco
San Francisco, California, USA
Philip Cohen, Principal Investigator, Ph: 202-994-3556
George Washington University Medical Center
Washington, District of Columbia, USA
Carl E. Freter, Principal Investigator, Ph: 202-687-8676
Vincent T. Lombardi Cancer Research Center, Georgetown University Medical Center
Washington, District of Columbia, USA
Margaret A. Fischl, Principal Investigator, Ph: 305-547-3838
University of Miami School of Medicine
Miami, Florida, USA
David Lyter, Principal Investigator, Ph: 312-296-7405
Illinois Masonic Cancer Center
Chicago, Illinois, USA
Jamie Hayden Von Roenn, Principal Investigator, Ph: 312-908-9412
Northwestern University Hematology/Oncology
Chicago, Illinois, USA
Richard Frederick Ambinder, Principal Investigator, Ph: 410-955-5617
Johns Hopkins Oncology Center
Baltimore, Maryland, USA
Jerome E. Groopman, Principal Investigator, Ph: 617-632-8561
Beth Israel Deaconess Medical Center
Boston, Massachusetts, USA
Bruce Jeffrey Dezube, Principal Investigator, Ph: 617-667-7082
Beth Israel Deaconess Medical Center
Boston, Massachusetts, USA
Timothy P. Cooley, Principal Investigator, Ph: 617-638-7520
Boston Medical Center
Boston, Massachusetts, USA
David Thomas Scadden, Principal Investigator, Ph: 617-726-5615
Massachusetts General Hospital
Boston, Massachusetts, USA
Lee Ratner, Principal Investigator, Ph: 314-454-0058
Washington University School of Medicine
Saint Louis, Missouri, USA
Abraham Chachoua, Principal Investigator, Ph: 212-263-6485
Kaplan Cancer Center
New York, New York, USA
David J. Straus, Principal Investigator, Ph: 212-639-8365
Memorial Sloan-Kettering Cancer Center
New York, New York, USA
Tony Waitung Cheung, Principal Investigator, Ph: 212-241-3934
Mount Sinai Medical Center, NY
New York, New York, USA
Zale Bernstein, Principal Investigator, Ph: 716-845-8075
Roswell Park Cancer Institute
Buffalo, New York, USA
Clayton Smith, Principal Investigator, Ph: 919-681-5255
Duke Comprehensive Cancer Center
Durham, North Carolina, USA |
